Stonepine Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Stonepine Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-285,300	Closed	-$1.29M	–	77
2025 Q2	$1.29M	Buy	285,300 +154,140	+118%	+$693K	1.26%	21
2025 Q1	$581K	Buy	+131,160	New	+$761K	0.57%	36

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Stonepine Capital Management's YMAB Position: Q3 2025 in Review

Stonepine Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 285,300 shares — an estimated $1.29M sold.

Stonepine Capital Management first reported a position in YMAB in Q1 2025 and held it in 2 quarters. The position peaked at $1.29M in Q2 2025. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Stonepine Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Stonepine Capital Management sold 285,300 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.29M.
Stonepine Capital Management first reported a position in Y-mAbs Therapeutics in Q1 2025 and held it in 2 quarters.
Stonepine Capital Management's Y-mAbs Therapeutics position peaked at $1.29M in Q2 2025.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.